Source comparison
MOTS-c AMPK Activation Complete Guide 2026: Comparison Table
Before diving into scenario-based applications, here's how MOTS-c compares to other AMPK activators used in metabolic research. MOTS-c Direct mitochondrial membrane signaling via CaMKK2 pathway 340% increase in skeletal muscle phospho-AMPK at 90 min High selec
This comparison does not assign a generated winner or score.
- Before diving into scenario-based applications, here's how MOTS-c compares to other AMPK activators used in metabolic research.
- MOTS-c
- Direct mitochondrial membrane signaling via CaMKK2 pathway
- 340% increase in skeletal muscle phospho-AMPK at 90 min
- High selectivity for skeletal muscle, moderate in liver and adipose
- 4–6 hours
- Age-related metabolic decline, insulin resistance, mitochondrial function
- Most tissue-specific; bypasses standard nutrient-sensing pathways entirely
- Metformin
- Inhibits mitochondrial Complex I, raises AMP:ATP ratio
- 180–220% increase in hepatic phospho-AMPK at 2–4 hours
- High selectivity for liver, minimal skeletal muscle activation
- 4–8 hours (dose-dependent)
- Type 2 diabetes, NAFLD, cancer metabolism
- Clinically proven but hepatocentric; muscle effects are indirect
- AICAR
- Mimics AMP, directly binds AMPK γ-subunit
- 250–300% increase across all tissues at 30–60 min
- Non-selective. Activates AMPK in all expressing tissues
- 2–3 hours
- Exercise mimetics, cardiac ischemia models
- Strongest direct activator but off-target adenosine receptor effects limit specificity
- Resveratrol
- Activates SIRT1, which indirectly activates AMPK via NAD+ modulation
- 60–120% increase in muscle/liver at 4–6 hours
- Moderate selectivity; depends on NAD+ availability
- 30–60 minutes
- Caloric restriction mimetics, longevity pathways
- Weakest AMPK activator; effects often attributed to SIRT1 rather than AMPK directly
- A-769662
- Allosteric activator binding AMPK β-subunit directly
- 400–500% increase in tissues with high β1 isoform expression
- High selectivity for β1-expressing tissues (muscle, heart)
- 6–8 hours
- Direct AMPK pharmacology, cardiac metabolism
- Most potent synthetic activator but poor oral bioavailability limits in vivo use